The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) hit a new 52-week high and has $15.87 target or 9.00% above today’s $14.56 share price. The 7 months bullish chart indicates low risk for the $328.63 million company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $15.87 price target is reached, the company will be worth $29.58M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 0.07% or $0.01 during the last trading session, hitting $14.56. About 117,195 shares traded hands or 62.67% up from the average. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 35.60% since April 22, 2016 and is uptrending. It has outperformed by 30.19% the S&P500.
Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on March, 7. They expect $-0.37 EPS, down 27.59% or $0.08 from last year’s $-0.29 per share. After $-0.18 actual EPS reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 105.56% negative EPS growth.
According to Zacks Investment Research, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom.”
Insitutional Activity: The institutional sentiment increased to 3.15 in 2016 Q2. Its up 1.65, from 1.5 in 2016Q1. The ratio increased, as 7 funds sold all Oxford Immunotec Global PLC shares owned while 13 reduced positions. 7 funds bought stakes while 23 increased positions. They now own 17.53 million shares or 3.01% less from 18.07 million shares in 2016Q1.
Bnp Paribas Arbitrage owns 864 shares or 0% of their US portfolio. Northern Trust has 0% invested in the company for 176,658 shares. New Leaf Venture Ptnrs Limited Liability Company last reported 10.67% of its portfolio in the stock. Wall Street Assoc reported 22,800 shares or 0.08% of all its holdings. Fosun Intll, a Hong Kong-based fund reported 467,551 shares. Axa has 603,270 shares for 0.02% of their US portfolio. State Street has 0% invested in the company for 244,102 shares. Bancshares Of New York Mellon Corporation holds 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 51,899 shares. Vanguard Group Inc has 0% invested in the company for 58,492 shares. Wells Fargo Company Mn accumulated 12,602 shares or 0% of the stock. Blackrock Advsrs Ltd Liability Corp holds 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 7,648 shares. Price T Rowe Md has 0% invested in the company for 813,215 shares. Sg Americas Lc reported 12,717 shares or 0% of all its holdings. Commercial Bank Of America Corp De has invested 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Spark Management Ltd Liability Company holds 0.03% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 39,200 shares.
Insider Transactions: Since November 8, 2016, the stock had 0 insider buys, and 2 selling transactions for $238,622 net activity. The insider Edwardson Peter sold 4,869 shares worth $68,615. SANDBERG RICHARD A had sold 12,000 shares worth $170,007 on Tuesday, November 8.
More important recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: Metrowestdailynews.com which released: “Oxford Immunotec Global PLC announces acquisition of Imugen Inc” on June 26, 2016, also Seekingalpha.com published article titled: “Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q3 2016 Results …”, Globenewswire.com published: “Oxford Immunotec Ranked Among Deloitte’s 2016 Technology Fast 500â„¢” on November 16, 2016. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) was released by: Reuters.com and their article: “BRIEF-Oxford Immunotec acquires Immunetics” with publication date: October 12, 2016.
OXFD Company Profile
Oxford Immunotec Global PLC, incorporated on August 16, 2013, is a global, commercial-stage diagnostics firm focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. The Company’s development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Through its early-stage immune-oncology program, it is investigating the use of its T-SPOT technology platform in cancer immunotherapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.